Aethlon director forfeits shares for RSU taxes

Aethlon Medical director Nicolas Gikakis reported a routine tax-related share withholding.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Aethlon Medical director Nicolas Gikakis reported a routine tax-related share withholding. Upon conversion of 5,454 vested restricted stock units into common stock, 2,182 shares were forfeited at a market price of $0.82 per share to cover taxes. After this non-market disposition, he directly holds 20,663 common shares.

Insider Trade Summary

Exercise Price or Tax Liability: 2,182 shares

Exercise Price or Tax Liability 1 txn

Insider Gikakis Nicolas

Role Director

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	2,182	$0.82	$2K

Holdings After Transaction: Common Stock — 20,663 shares (Direct)

Footnotes (1)

F1. The Reporting Person forfeited 2,182 shares of common stock upon conversion of an aggregate 5,454 vested and outstanding restricted stock units into shares of common stock to cover tax withholdings, using the market price of the issuer's common stock at the time of forfeiture. These restricted stock units were part of the grant reported in Table I of the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on April 17, 2026.

Key Figures

Shares forfeited for tax withholding: 2,182 shares RSUs converted: 5,454 units Market price used: $0.82 per share +2 more

5 metrics

Shares forfeited for tax withholding 2,182 shares Tax-withholding disposition at $0.82 per share

RSUs converted 5,454 units Vested restricted stock units converting into common stock

Market price used $0.82 per share Price at time of forfeiture for tax calculation

Shares held after transaction 20,663 shares Director’s direct common stock holdings post-disposition

Transaction code F Payment of tax liability by delivering securities

Key Terms

restricted stock units, tax withholdings, forfeited

3 terms

restricted stock units financial

"conversion of an aggregate 5,454 vested and outstanding restricted stock units into shares of common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholdings financial

"shares of common stock to cover tax withholdings, using the market price"

forfeited financial

"The Reporting Person forfeited 2,182 shares of common stock upon conversion"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Aethlon Medical (AEMD) director Nicolas Gikakis report?

Director Nicolas Gikakis reported a tax-withholding disposition of 2,182 Aethlon Medical common shares. These were forfeited when 5,454 vested restricted stock units converted into shares, using a market price of $0.82 per share to satisfy tax obligations.

Was the Aethlon Medical (AEMD) Form 4 transaction an open-market sale?

No, the Form 4 transaction was not an open-market sale. The 2,182 Aethlon Medical shares were forfeited to cover tax withholdings upon RSU conversion, a non-market, administrative disposition typically tied to equity compensation rather than discretionary selling.

How many Aethlon Medical (AEMD) shares does Nicolas Gikakis hold after this filing?

After the reported tax-withholding disposition, Nicolas Gikakis directly holds 20,663 Aethlon Medical common shares. This figure reflects his position following forfeiture of 2,182 shares associated with the conversion of 5,454 vested restricted stock units into stock.

What equity award triggered the Aethlon Medical (AEMD) tax-withholding disposition?

The disposition was triggered when 5,454 vested and outstanding restricted stock units converted into Aethlon Medical common shares. As part of this conversion, 2,182 shares were forfeited to satisfy tax withholdings based on the market price at the time of forfeiture.

How was the tax withholding amount determined in the Aethlon Medical (AEMD) Form 4?

The tax withholding amount was determined using the market price of Aethlon Medical common stock at the time of forfeiture, disclosed as $0.82 per share. At that price, 2,182 shares from the RSU conversion were forfeited to cover the reporting person’s tax obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/01/2026 - 05:15 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gikakis Nicolas

(Last)

(First)

(Middle)

11555 SORRENTO VALLEY RD, STE 203

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AETHLON MEDICAL INC [ AEMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/30/2026		F		2,182⁽¹⁾	D	$0.82	20,663	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Reporting Person forfeited 2,182 shares of common stock upon conversion of an aggregate 5,454 vested and outstanding restricted stock units into shares of common stock to cover tax withholdings, using the market price of the issuer's common stock at the time of forfeiture. These restricted stock units were part of the grant reported in Table I of the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on April 17, 2026.

	/s/ Nicolas Gikakis By: James B. Frakes, Attorney-in-fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR